The U.S. Food and Drug Administration (FDA) has granted approval to Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid), an oral antibiotic, for the treatment of uncomplicated urinary tract infections (UTIs) in adult women. This approval addresses a significant gap in treatment options for women who have limited or no alternative oral antibacterial therapies available.
Addressing Unmet Needs in UTI Treatment
UTIs are common bacterial infections, particularly among women. Orlynvah is specifically indicated for uncomplicated UTIs caused by susceptible bacteria in women who have exhausted other oral treatment options. This approval provides a new tool for healthcare providers facing the challenge of recurrent or resistant UTIs.
The drug is expected to be available around mid-2025.
Ottimo Pharma's Immuno-Oncology Approach
In other news, Ottimo Pharma, a new company led by former Seagen CEO David Epstein, is focusing on developing a novel cancer therapy. The company's experimental antibody targets both PD-1 and VEGF, two proteins involved in immune regulation and angiogenesis, respectively. This dual-targeting approach represents a promising strategy in immuno-oncology.
